We are utilizing our Cas-CLOVER technology to develop our first allogeneic CAR-T for BCMA, P-BCMA-ALLO1, planned for next year. We also plan to initiate patient dosing in our P-PSMA-101 trial for prostate cancer patients early next year, in our first product candidate in solid tumors. Simultaneously, our P-MUC1C-101 program is currently in development and has the potential to treat many different forms of cancer, from lung to ovarian. See our Pipeline page for more information.
Innovations at Poseida are oriented toward developing treatments and cures using our cutting-edge technologies to increase efficiency in gene delivery, most recently with development of synthetic nanoparticles having the capability to deliver either DNA or RNA in vivo.
Please click Technology to learn more about our proprietary capabilities, and Pipeline to view our current pre-clinical and clinical development program including cell therapies for multiple myeloma, prostate cancer and more.